Novo Nordisk A/S (NYSE:NVO) Shares Sold by Northeast Investment Management

Northeast Investment Management lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,405 shares of the company’s stock after selling 155 shares during the quarter. Northeast Investment Management’s holdings in Novo Nordisk A/S were worth $293,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. WCM Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 1.0% during the 4th quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock worth $345,588,000 after purchasing an additional 40,475 shares during the period. Advisory Resource Group boosted its stake in Novo Nordisk A/S by 61.1% during the fourth quarter. Advisory Resource Group now owns 11,985 shares of the company’s stock worth $1,031,000 after buying an additional 4,544 shares during the period. Apollon Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 13.9% during the fourth quarter. Apollon Wealth Management LLC now owns 44,228 shares of the company’s stock valued at $3,804,000 after acquiring an additional 5,393 shares during the last quarter. Quattro Financial Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $299,000. Finally, Platform Technology Partners lifted its holdings in shares of Novo Nordisk A/S by 38.7% in the 4th quarter. Platform Technology Partners now owns 5,677 shares of the company’s stock worth $488,000 after acquiring an additional 1,584 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.9 %

NVO opened at $86.39 on Friday. The firm has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The business’s 50 day moving average is $91.46 and its two-hundred day moving average is $111.51. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Analysts Set New Price Targets

Several research firms recently weighed in on NVO. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.